Therapeutic Asset Ratings
3,272 results matching 1 filter
91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Nivolumab
Esophageal Melanoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Undifferentiated Carcinoma Of Esophagus
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Extrahepatic Bile Duct Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Extramammary Paget Disease
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Sebaceous Adenocarcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Fallopian Tube Adenocarcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Fallopian Tube Transitional Cell Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Fibromyxoid Tumor
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Gallbladder Melanoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Gastric Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Gastric Squamous Cell Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Undifferentiated Carcinoma Of Stomach
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Gestational Trophoblastic Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Lung Giant Cell Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Hidradenocarcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Cervical Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Infiltrating Bladder Lymphoepithelioma-Like Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Nested Variant Infiltrating Bladder Urothelial Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Large Cell Neuroendocrine Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Hypopharynx Squamous Cell Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Laryngeal Squamous Cell Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Oral Cavity Squamous Cell Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Low Grade Glioma
National Cancer Institute (NCI)
P2
CCC
(53)
Nivolumab
Lung Sarcomatoid Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Showing 1726 to 1750 of 3,272 assets
Previous
Page 70 of 131
Next